The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
Corey Allan Carter
No relevant relationships to disclose
Arun Rajan
No relevant relationships to disclose
Eva Szabo
No relevant relationships to disclose
Sean Khozin
No relevant relationships to disclose
Anish Thomas
No relevant relationships to disclose
Christina E. Brzezniak
No relevant relationships to disclose
Udayan Guha
No relevant relationships to disclose
L. Austin Doyle
No relevant relationships to disclose
Corrine Keen
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
Liqiang Xi
No relevant relationships to disclose
Mark Raffeld
No relevant relationships to disclose
Karen L. Reckamp
No relevant relationships to disclose
Stephen Koehler
No relevant relationships to disclose
Barbara Jennifer Gitlitz
No relevant relationships to disclose
Ravi Salgia
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose
Everett E. Vokes
No relevant relationships to disclose
Giuseppe Giaccone
No relevant relationships to disclose